The Industry

October 2010
Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p7
The article offers news briefs related to pharmaceutical industries in the U.S. Kevin Kruse was appointed as the new executive director of the Society of Pharmaceutical and Biotech Trainers (SPBT). Bristol-Myers Squibb Co. has agreed to take on the biopharma company ZymoGenetics Inc. which hopes to strengthen their development of the Hepatitis C portfolio. Mylan Pharmaceutical Inc. has acquired Bioniche Pharma USA LLC, an injectable pharmaceutical company.


Related Articles

  • Pharma: Other News To Note.  // BioWorld Today;5/20/2013, Vol. 24 Issue 96, p7 

    This section offers news briefs in the U.S. pharmaceutical industry as of May 20, 2013 including Bristol-Myers Squibb Co.'s plan to voluntary delist its two dollars convertible preferred stock from the New York Stock Exchange, the distribution of the Fenofibrate Tablets from Mylan...

  • NEWS FOCUS.  // Pharmaceutical Representative;Jan2010, Vol. 40 Issue 1, p7 

    The article offers news briefs in the pharmaceutical industry in the U.S. Pfizer Inc. strengthens its research and development facilities after its acquisition of Wyeth. Bristol-Myers Squibb Co. agrees with Tranzyme Pharma for its drug development. Novo Nordisk A/S will license the fully-human...

  • ZymoGenetics Sold to Bristol-Myers.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p45 

    The article reports that ZymoGenetics Inc. will be sold to New York-based Bristol-Myers Squibb Co. for 9.75 dollar-per-share in 2010.

  • MYLAN PHARMACEUTICALS, INC. V. THOMPSON.  // Berkeley Technology Law Journal;Annual Review 2002, Vol. 17 Issue 1, p155 

    Presents the legal case involving Mylan Pharmaceuticals Inc. v. Bristol-Myers Squibb Co. on the approval of drug products in the U.S. Use of generic drug; Treatment of anxiety through buspirone hydrochloride; Lists of the second patent from the Orange Book.

  • Mylan Pharmaceuticals.  // Drug Store News;7/23/2001, Vol. 23 Issue 9, p44 

    Introduces Mylan Pharmaceuticals Incorporated's brand of buspirone hydrochloride tablets, an alternative to Bristol-Myers Squibb's BuSpar. Mechanics of its dosing flexibility; Advantage of the Mylan drug.

  • CORPORATE.  // MondayMorning;9/26/2011, Vol. 19 Issue 34, p2 

    The article offers news briefs related to the U.S. pharmaceutical industry. Lamberto Andreotti, chief executive officer (CEO) of Bristol-Myers Squibb Co., says the company intends to use its cash hoard to gain new drugs through deals with other drugmakers. Insurer WellPoint Inc. is planning to...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;9/26/2011, Vol. 19 Issue 34, p4 

    The article offers news briefs related to the pharmaceutical industry in the U.S. According to a report in the journal "Neuron," scientists have discovered a gene responsible for Lou Gehrig's disease and a related brain disorder. According to a study, Bristol-Myers Squibb Co.'s experimental...

  • UNITED STATES PHARMACEUTICALS.  // Acquisdata Industry SnapShot: United States - Pharmaceuticals;11/ 7/2014, Issue 2071, preceding p1 

    The article focuses on the pharmaceutical industry in U.S., including Bristol-Myers Squibb Co./Otsuka's Abilify's share in schizophrenia, Merck & Co.'s rating on shares reiterated by Standard and Poor (S&P) Equity Research, and Johnson & Johnson's (JNJ) Dow Jones Industrial Average (DJIA).

  • The Industry.  // Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p7 

    The article offers news briefs related to the U.S. pharmaceutical industry. Aton Pharma Inc. has acquired the marketing rights of Bristol-Myers Squibb Co.'s Lodosyn (carbidopa) tablets, indicated for use with levodopa to treat symptoms of Parkinson's disease. Astellas Inc. and OSI...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics